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Addition of Vasopressin to Norepinephrine
as Independent Predictor of Mortality in Patients
with Refractory Septic Shock: An Observational Study
SCOTT T. MICEK,1 POORVI SHAH,2 JAMES M. HOLLANDS,1 RINA A. SHAH,1
WILLIAM D. SHANNON,3 and MARIN H. KOLLEF4

ABSTRACT
Objective: To identify predictors of 28-day mortality among patients with refractory septic
shock treated with norepinephrine with or without vasopressin.
Design: Prospective observational cohort study.
Setting: A 1,200-bed academic medical center.
Patients: One hundred thirty-seven patients with septic shock treated with norepinephrine
with or without vasopressin.
Interventions: None.
Measurements and Main Results: The 28-day mortality rate was 37.2% (n  51). By multivariate analysis, significant predictors of death were norepinephrine plus vasopressin administration (adjusted odds ratio [AOR], 13.96; 95% confidence interval [CI] 6.47, 30.08; p 
0.001), lack of goal-directed fluid administration during initial resuscitation (AOR 15.82; 95%
CI 6.16, 40.61; p  0.003), inappropriate initial antimicrobial therapy (AOR 8.95; 95% CI 2.93,
27.33; p  0.05), and higher Acute Physiology and Chronic Health Evaluation (APACHE) II
score (AOR 1.14; 95% CI 1.07, 1.21; p  0.033). Patients who received norepinephrine plus vasopressin (n  68) had a significantly higher mortality rate than patients managed with norepinephrine alone (n  69) 28 days after the initiation of vasopressors (54.4% vs. 20.3%; p 
0.001). This finding was confirmed in patients matched optimally across treatment groups.
Conclusions: Our study found an association between the use of norepinephrine plus vasopressin and 28-day mortality in refractory septic shock. In view of its known mechanism
of action, vasopressin contributed to this excess mortality. Further recommendations regarding the use of vasopressin await the results of large randomized trials evaluating its efficacy
and safety for septic shock.

S

EVERE SEPSIS is an infection-induced syndrome resulting in a systemic inflammatory
response complicated by dysfunction of at least
one organ system [1]. In the United States, ap-

proximately 750,000 cases of sepsis occur each
year [2,3]. The mortality rate ranges from 30%
to 50%, increasing with advancing age [3,4].
The complex pathophysiology of sepsis in-
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cludes a series of interacting pathways of immune stimulation, immune suppression, hypercoagulation, and hypofibrinolysis [5,6].
Cardiovascular management plays an important role in the treatment of septic shock.
Hypotension occurs secondary to failure of
vasoconstriction by vascular smooth muscle,
resulting in peripheral vasodilation [7,8]. When
hypotension persists despite goal-directed
fluid resuscitation, exogenous catecholamines
are administered to increase the mean arterial
pressure (MAP). Selecting the most appropriate initial vasopressor agent for the management of septic shock remains a challenge.
Catecholamines (e.g., norepinephrine and
dopamine) are considered first-line agents
[9,10], but they often yield poor hemodynamic
responses as the result of multiple mechanisms
[8]. This difficulty has stimulated interest in
other agents, such as vasopressin, for managing sepsis-induced hypotension.
Vasopressin is an endogenous hormone synthesized in the hypothalamus and stored in the
posterior pituitary gland, from which it is secreted in response to appropriate stimuli
[11–13]. In addition to its antidiuretic effects,
vasopressin has potent smooth muscle vasoconstricting properties that make it useful in
raising the MAP in septic shock [7,8,11,12,14].
During the early phases of septic shock, circulating vasopressin concentrations are elevated,
but as hypotension persists, these concentrations decrease, and neurohypophyseal and
plasma concentrations become deficient [13,15–
17]. Vasopressin deficiency is one of the mechanisms involved in the development of vasodilatory shock [8], which has led to various
studies showing that exogenous vasopressin
increases the MAP while reducing the necessary norepinephrine dosage, and that it may improve urine output [18–22]. However, there
may be negative consequences associated with
administration of vasopressin to patients with
septic shock, including myocardial and
splanchnic ischemia [19].
The following is a description of an observational prospective study of critically ill patients with septic shock managed with norepinephrine with or without vasopressin for
hemodynamic support. The purpose was to
identify risk factors associated with 28-day all-
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cause mortality, with a particular interest in the
effects of vasopressin administration.

PATIENTS AND METHODS
Study location and patients
The study was conducted in the intensive
care units (ICUs) (medical, surgical-trauma,
cardiothoracic, neurologic-neurosurgical, cardiac) of a 1,200-bed academic medical center:
Barnes-Jewish Hospital/Washington University Medical Center in St. Louis, MO, from December 2003 to December 2004. These ICUs
are closed units employing multidisciplinary
rounds directed by a physician board-certified
in critical care. The study was approved by the
Washington University School of Medicine Human Studies Committee. Informed consent was
obtained for collection of patient data.
One hundred thirty-seven patients (73 men
and 64 women) met the criteria for volume-refractory septic shock necessitating administration of either norepinephrine alone (n  69) or
norepinephrine plus vasopressin (n  68). The
mean age of the patients was 59.2  15.9 years.
The mean Acute Physiology and Chronic
Health Evaluation (APACHE) II and Sequential Organ Failure Assessment (SOFA) scores
were 26.2  6.1 and 9.4  3.1, respectively.
Eighty-four patients (61.3%) were treated in
medical ICUs and 53 (38.7%) in surgical ICUs.
Study entry criteria and vasopressor
administration
Clinical criteria required for enrollment in
the study were: (1) The presence of two or more
signs of the systemic inflammatory response
syndrome; (2) an infection documented by positive culture, radiographic findings consistent
with infection, or a clinical syndrome associated with a high probability of infection; and
(3) vasodilatory volume-refractory shock necessitating administration of norepinephrine or
norepinephrine plus vasopressin for a minimum of six hours to maintain a minimum target MAP  55 mm Hg (routine target MAP in
patients without refractory shock is 60 to 65
mm Hg). In accord with the Surviving Sepsis
Campaign Guidelines, vasopressin was given
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to volume-refractory, norepinephrine-dependent patients at a dose of 0.04 units/min [9].
The prescription of norepinephrine alone or
norepinephrine plus vasopressin was not
based on specified hemodynamic cut-offs (i.e.,
norepinephrine dose of  0.5 mcg/kg/min or
organ failure progression) but was solely at the
discretion of the board-certified critical care
specialist directing the patient’s care. Patients
given dopamine for hemodynamic stabilization were excluded from the analysis to allow
a more uniform analysis. Patients with refractory shock despite appropriate vasopressor administration were included. Vasopressors were
tapered by discontinuing the vasopressin infusion first, when employed, and then reducing
the norepinephrine infusion by increments of
0.05 to 1.0 mcg/kg/min.
Study design and data collection
A prospective, observational cohort study
design was used, segregating patients who received vasopressors according to 28-day survival to identify potential risk factors for patient death. All-cause mortality at 28 days after
the initiation of vasopressors for septic shock
was determined a priori to be the dependent
variable of interest. Secondary analyses included a comparison of patients who received
norepinephrine alone with those given norepinephrine plus vasopressin, and evaluation of
cardiovascular and renal organ dysfunction or
failure over time by calculating SOFA scores
for each parameter.
For all study patients, the following characteristics were recorded during the first 24 h of
vasopressor administration: Age, sex, weight,
primary service (medical [cardiac, neurologic,
and general medical patients] or surgical [cardiothoracic, neurosurgical and general surgical
patients]), APACHE II score, the number of organs failing, the need for mechanical ventilation, and the use of dobutamine. Additionally,
the source of infection and the presence of a
positive culture (e.g., blood, respiratory specimen, urine, stool, wound specimen) were
recorded on identification. Other specific
process-of-care variables examined were the total volume of fluid administered in the six-hour
period prior to initiation of vasopressors, the
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use of invasive monitoring to guide fluid resuscitation in the first six hours after presentation, the presence or absence of appropriate initial antimicrobial treatment of the identified
infection, the administration of corticosteroids
or drotrecogin alfa (activated), daily renal replacement therapy, and blood glucose control.
A daily computerized list of all patients
started on norepinephrine or vasopressin was
generated by the Washington University
School of Medicine’s Medical Informatics
Department, which allowed identification of
study patients. One of the investigators made
daily rounds on all study patients, recording
relevant data from the medical records, bedside
flowsheets, and the hospital’s mainframe computer for reports of microbiologic studies
(gram stains and cultures of blood, urine, sputum, lower respiratory tract specimens, tissue,
and wounds). All pharmacotherapies administered in the emergency department, general
medical or surgical ward, and ICU were evaluated using patients’ medical records and the
hospital’s computerized bedside workstations
(EMTEK Health Care Systems, Inc., Tempe,
AZ, and Clinical Desktop, BJC Healthcare, St.
Louis, MO).
Definitions
All definitions were selected a priori as a part
of the original study design. Norepinephrine
dependency was defined as the inability to
wean the patient off the norepinephrine infusion during the first six hours of its administration, or the addition of a vasopressin infusion. The fluid resuscitation during the six
hours immediately preceding the initiation of
vasopressors was evaluated. The types of fluids administered included crystalloid solutions
(0.9% sodium chloride or lactated Ringer’s) or
colloid solutions (fresh frozen plasma, albumin, or 6% hydroxyethyl starch). Invasive goaldirected monitoring was defined as the documentation of one or more of the following: (1)
Central venous pressure to a goal of 8–12 mm
Hg; (2) pulmonary artery occlusion pressure to
a goal of 14–18 mm Hg; or (3) the corrected flow
time (FTc) measured by esophageal Doppler
probe (goal  330 milliseconds) during the volume resuscitation phase of therapy. For the
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purposes of this investigation, appropriate antimicrobial treatment was defined as the microbiologic documentation of an infection (i.e.,
a positive culture result) that was being treated
effectively on the basis of the in vitro susceptibility results at the time of its identification.
Corticosteroid therapy was composed of hydrocortisone 200–300 mg/day or its equivalent
for seven consecutive days or until death. Patients were not required to have adrenal insufficiency on the basis of cortisol concentrations
determined randomly or an adrenocorticotropic hormone (ACTH) stimulation test to
receive corticosteroid. The morning blood glucose concentration was measured daily between 3:00 and 6:00 A.M. throughout the ICU
stay. The average of the morning blood glucose
concentrations while the patient was in the ICU
was evaluated.
Calculations of APACHE II and SOFA scores
were made on the basis of clinical data available for the first 24 h of vasopressor administration [24]. The definition for systemic inflammatory response syndrome was that
proposed by the American College of Chest
Physicians/Society of Critical Care Medicine
Consensus Conference [25]. The definition of
organ failure was based on The Recombinant
Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial and
included one or more of the following: (1) Cardiovascular–vasopressors required to maintain
the systolic blood pressure  90 mm Hg or the
MAP  70 mm Hg; (2) renal–urine output
 0.5 mL/kg of body weight/h for one hour;
(3) respiratory–ratio of the partial pressure of
arterial oxygen to the fraction of inspired oxygen (PaO2/FIO2)  250 on mechanical ventilation; (4) hematologic–platelet count  80,000/
mm3 or a decrease by 50% over the previous
three days; (5) unexplained metabolic acidosis–pH  7.30 or lactate  4 mmol/L [26]. Sequential cardiovascular and renal SOFA scores
were calculated using the worst value for each
parameter during each 24-h period [27].
Statistical analysis
Continuous data are reported as mean 
standard deviation, and the Student t-test was
employed for comparison of means between
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groups. Categorical variables are reported as
frequency distributions, and the chi-square or
Fisher exact test was used to test whether differences existed between groups. Nonparametric data were analyzed with the MannWhitney U test. These data are presented as
median values with 25th and 75th percentiles.
After these univariate analyses, multivariable
logistic regression adjusting for time at risk for
the outcome event was undertaken to identify
independent risk factors for in-hospital death.
Risk factors significant at the 0.2 level by univariate analysis were entered in the model. Adjusted odds ratios (AORs) and their corresponding 95% confidence intervals (CIs) are
reported. Kaplan-Meier curves representing
the time from the start of vasopressor infusion
to death up to 28 days later were compared using the log-rank test. All tests were two-tailed,
and a p value  0.05 was defined as statistical
significance. Optimal bipartite graph matching
using SAS 9.1 macros (SAS Institute, Cary,
NC) was done to match patients receiving
norepinephrine alone with the most similar patient receiving norepinephrine plus vasopressin [28]. Variables used in the matching are
listed in Tables 1 and 2 with the exception of
volume administered in the six hours prior to
vasopressor administration (secondary to missing data in nine patients) and appropriate initial antimicrobial administration (not all patients had positive cultures). The paired data
resulting from bipartite graph matching were
compared using McNemar’s test. Statistical
analyses were done with the SPSS 10.1 software package (SPSS, Inc., Chicago, IL) SAS 9.1,
and the MATCH macro, available from the
Department of Biostatistics, Mayo Clinic,
Rochester, MN.

RESULTS
The 28-day mortality rate for the entire cohort was 37.2%. The results of univariate analysis for patient characteristics according to 28day survival status are presented in Table 1.
Nonsurvivors were significantly older, had statistically greater APACHE II and SOFA scores,
and also had a higher number of organs with
acquired failure compared with the survivors.

VASOPRESSIN IN REFRACTORY SEPTIC SHOCK
TABLE 1.

Age (yrs)
No. (%) male
Weight (kg)
No. (%) patient type
Medical
Surgical
APACHE II score
SOFA score
No. (%) having mechanical
ventilation
No. of acquired organ failures
Reason for ICU admission
Post-op (non-trauma)
Post-op (trauma)
ARDS
Sepsis
Acute MI
Other
Infection source
Lung
Abdomen
Urine
Other
No. (%) positive cultures
No. (%) positive blood cultures
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PATIENT CHARACTERISTICS

Norepinephrine
(n  69)

Norepinephrine
plus
vasopressin
(n  68)

0.040
0.178
0.884

60.2  14.2
36 (52.2)
78.4  21.5

58.3  17.7
36 (52.9)
91.9  44.5

0.477
0.928
0.025

0.086

43
26
25.3
9.1
53

41
26
27.1
9.8
66

0.808

28-day
survivors
(n  86)

28-day
nonsurvivors
(n  51)

P value

57.1  16.4
49 (57.0)
85.5  35.1

62.9  14.8
23 (45.1)
84.5  36.2

48
38
24.5
8.8
71

36
15
28.9
10.5
47

(55.8)
(44.1)
 5.5
 2.9
(82.6)

(70.6)
(29.4)
 6.3
 3.1
(92.2)

0.001
0.001
0.116

2.5  0.9

3.1  0.9

0.001

23
5
10
37
9
2

(26.7)
( 5.8)
(11.6)
(43.0)
(10.5)
( 2.3)

10
0
7
27
6
1

(13.7)
(52.9)
(11.8)
( 1.9)

40
30
7
9
66
27

(46.5)
(34.9)
( 8.1)
(10.5)
(76.7)
(31.4)

21
22
2
6
34
20

(41.2)
(43.1)
( 3.9)
(11.8)
(66.7)
(39.2)

(19.6)

(60.3)
(39.7)
 5.8
 3.0
(97.1)

0.086
0.174
0.001

2.5  0.90

3.1  0.9

0.001

0.100

17
1
7
33
9
2

(24.6)
( 1.4)
(10.1)
(47.8)
(13.0)
( 2.9)

14
4
10
28
6
6

(20.6)
( 5.9)
(14.7)
(41.2)
( 8.8)
( 8.8)

0.448

0.774

32
24
6
8
54
25

(45.7)
(34.3)
( 8.6)
(11.3)
(78.3)
(36.3)

31
26
2
8
46
22

(46.3)
(38.8)
( 3.0)
(11.9)
(67.6)
(32.4)

0.554

0.199
0.351

(62.3)
(37.7)
 6.4
 3.2
(75.4)

P value

0.162
0.633

APACHE  Acute Physiology and Chronic Health Evaluation; SOFA  Sequential Organ Failure Assessment Score;
ICU  intensive care unit; ARDS  acute respiratory distress syndrome; MI  myocardial infarction.

Table 2 displays the univariate analysis for the
process-of-care variables. The administration
of vasopressin and corticosteroids, as well as
the lack of goal-targeted fluid administration
during initial resuscitation, occurred significantly more often in the nonsurvivors than in
the survivors.
Independent risk factors for 28-day mortality, as compiled by multiple logistic regression
analysis, are shown in Table 3. The administration of vasopressin, the lack of goal-directed
volume resuscitation, higher APACHE II
scores, and inappropriate antimicrobial therapy were independently associated with 28day mortality. Twenty-eight-day survivors had
significantly longer median durations of intensive care (12.5 days; interquartile range [IQR]
6 to 30 days vs. 9 days, IQR 6 to 12.5 days; p 
0.002) and hospital lengths of stay (33 days; IQR
15 to 53 days vs. 12 days, IQR 7.5 to 19 days;
p  0.001) compared with nonsurvivors.

A comparison of patients who received
norepinephrine with those receiving norepinephrine plus vasopressin revealed several differences in baseline characteristics and process-of-care variables. Patients who received
norepinephrine plus vasopressin had a statistically greater body mass, number of acquired
organ system derangements, and mechanical
ventilation requirement and were significantly
more likely to be given drotrecogin alfa (activated) than those who received norepinephrine
alone (Tables 1 and 2). Twenty-eight days after
the start of vasopressor administration, 14 of 69
patients (20.3%) managed with norepinephrine
alone and 37 of 68 (54.4%) treated with norepinephrine plus vasopressin had died (p 
0.001). A Kaplan-Meier analysis of survival at
28 days yielded similar results (p  0.001) (Fig.
1). Additionally, the administration of vasopressin in combination with norepinephrine in
graph-matched patients was associated with a
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TABLE 2.
28-day
survivors
(n  86)

No. (%) appropriate initial
62
antimicrobial treatment
Volume administration (mL)a
2549.0
Volume administration (mL/kg)a
31.2
No. (%) goal-directed fluid
34
administration
Type of goal-directed
hemodynamic monitoring, n (%)
Central venous pressure
31
Pulmonary capillary wedge
2
pressure
Esophageal Doppler probe
5
No. (%) vasopressin
31
No. (%) dobutamine
9
No. (%) corticosteroids
46
No. (%) drotrecogin alfa (activated)
19
No. (%) renal replacement therapy
16
Blood glucose (mg/dL)
145.4
aTotal

(93.9)

PROCESS-OF-CARE VARIABLES
28-day
nonsurvivors
(n  51)

P value

30 (88.2)

0.188

 1791.0 2159.0  1540.0
 21.1 28.9  25.1
(39.5)
10 (19.6)

7
1
2
(36.0)
37
(10.5)
10
(53.5)
36
(22.1)
16
(18.6)
12
 36.0 152.7

Norepinephrine
(n  69)

Norepinephrine
plus
vasopressin
(n  68)
P value

50 (94.3)

42 (91.3)

0.557

0.220 2321.0  1767.0 2515.0  1654.0 0.523
0.575 29.1  19.9 31.8  25.2 0.503
0.016
20 (29.0)
24 (35.3)
0.429

0.005
0.888

18
0

20
3

0.335
3
(72.5)
0.001
(19.6)
0.134
7
(70.6)
0.048
40
(31.3)
0.229
10
(23.5)
0.490
12
 47.2 0.310 146.5

4
—
(10.1)
12
(58.0)
42
(14.5)
25
(17.4)
16
 45.1 149.7

0.664
0.078
0.683
—
(17.6)
(61.8)
(36.7)
(23.5)
 35.4

0.204
0.651
0.003
0.373
0.645

intravenous fluid administration in the six-hour time window prior to initiation of vasopressors.

significantly higher 28-day mortality rate than
vasopressor support with norepinephrine
alone (p  0.001). The median duration of intensive care (9 days; IQR 6–16 days vs. 11 days,
IQR 6–22 days; p  0.310) and hospital length
of stay (20 days; IQR 6–30 days vs. 19 days, IQR
11–39 days; p  0.356) was not statistically different in patients receiving norepinephrine
alone vs. norepinephrine plus vasopressin, respectively.
Figure 2 displays the norepinephrine dose
and duration of infusion when vasopressin was
added for management of shock. The median
dose of norepinephrine when vasopressin was
added was 0.3 mcg/kg/min (IQR 0.16–0.56
TABLE 3.

MULTIVARIABLE ANALYSIS

mcg/kg/min; mean  SD 0.39  0.28 mcg/
kg/min), and the median time on norepinephrine before vasopressin was initiated was 8 h
(IQR 3.75–19.5 h; mean  SD 27.5  52.8 h).
There was no statistical correlation between the
dose and time on norepinephrine when vasopressin was initiated (Spearman coefficient
0.119; p  0.339). The median dose of norepinephrine when vasopressin was added for hemodynamic support did not differ between
survivors and nonsurvivors (0.23 mcg/kg/
min; IQR 0.14–0.53 mcg/kg/min vs. 0.38
mcg/kg/min; IQR 0.25–0.57 mcg/kg/min; p 
0.138). Similarly, the median amount of time
patients were managed with norepinephrine

OF INDEPENDENT

RISK FACTORS

Adjusted
odds ratio
Norepinephrine plus vasopressin administration
Lack of goal-directed volume resuscitation
Increasing APACHE II score, per point
Inappropriate initial antimicrobial therapy

13.96
15.82
1.14
8.95

FOR

28-DAY MORTALITY
95% CI
6.47,
6.16,
1.07,
2.93,

30.08
40.61
1.21
27.33

P value
0.001
0.003
0.033
0.050

APACHE  Acute Physiology and Chronic Health Evaluation; CI  confidence interval.
Covariates not included in table had p value  0.05. These were corticosteroid administration, patient type (medical
or surgical), mechanical ventilation, amount of intravenous fluid administered six hours prior to initiation of vasopressors, use of dobutamine, and administration of drotrecogin alfa (activated). Hosmer-Lemeshow goodness of fit test
p  0.47.
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FIG. 1. Kaplan-Meier curves comparing probability of survival at day 28 for patients treated with norepinephrine
alone and those receiving norepinephrine plus vasopressin (p  0.001; log-rank test).

FIG. 2. Scatter plot of norepinephrine (NE) dose and infusion duration when vasopressin (VP) was initiated. Open
triangles represent nonsurvivors and open circles survivors at day 28 after initiation of vasopressors. (Spearman coefficient -0.119; p  0.339).
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before vasopressin was initiated did not differ
between survivors and nonsurvivors (9 h; IQR
6–21 h vs. 8 h; IQR 3–16 h; p  0.204). The overall duration of norepinephrine infusion for survivors and nonsurvivors was not statistically
different (4.8  4.1 vs. 5.1  2.8 days; p 
0.681). Conversely, patients who received vasopressin had statistically longer durations of
norepinephrine infusion than those who did
not (5.7  4.0 vs. 4.2  3.2 days; p  0.024).
The addition of vasopressin to norepinephrine did not result in better cardiovascular or
renal function when evaluated by SOFA scores
over a 14-day period (Fig. 3). The mean cardiovascular SOFA scores representing the norepinephrine dose requirement were statistically higher in patients managed with the
combination of norepinephrine and vasopressin on days 2, 3, 5, and 7 of vasopressor
therapy than in those treated with norepinephrine alone. There were no observed differences in kidney function over 14 days when
comparing renal SOFA scores for patients who
received vasopressin with those who did not.
A subgroup analysis of 28-day survivors and
nonsurvivors was performed comparing baseline characteristics and process-of-care variables in patients treated with both norepinephrine and vasopressin (n  68). Significant
differences in baseline characteristics between
survivors and nonsurvivors included age
(51.9  18.3 years vs. 63.6  15.5 years; p 
0.006), APACHE II score (25.2  4.1 vs. 28.6 
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6.6; p  0.014), and having a positive blood culture (19.4% vs. 43.2%; p  0.036). Significant
differences in process-of-care variables between survivors and nonsurvivors included
the use of goal-directed fluid administration
during the initial phase of resuscitation (54.8%
vs. 18.9%; p  0.002) and the administration of
corticosteroids (48.4% vs. 73.0%; p  0.038).
DISCUSSION
Our study found patients with septic shock
who were initially volume resuscitated without goal-directed invasive hemodynamic monitoring and those who received inappropriate
initial antimicrobial therapy to be at higher risk
of death by 28 days. This study also substantiated our previous finding that vasopressin in
doses up to 0.04 units/min administered in
combination with norepinephrine for hemodynamic support is an independent predictor of
28-day mortality.
Previous studies have shown that vasopressin may have beneficial short-term, organsparing effects in patients with septic shock.
However, because of the lack of clinical outcome data, vasopressin has been recommended
for use only in patients who are volume-refractory and require norepinephrine in doses
exceeding 0.5 mcg/kg/min [9,20]. As a result
of numerous investigations that have found vasopressin to have catecholamine-sparing ef-

FIG. 3. Mean SOFA scores for cardiovascular and renal organ systems in patients receiving norepinephrine alone
(solid bars) and norepinephrine plus vasopressin (striped bars). Difference between mean scores was significant for
cardiovascular system on days 2, 3, 5, and 7 (p  0.05).
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fects [19,20,29], administration of this agent to
patients requiring low-dose norepinephrine
has been reported [22] and tested at many medical centers. The best example of the catecholamine-sparing effect was demonstrated in
a randomized, double-blind study conducted
by Patel et al. [21], in which patients requiring
norepinephrine for septic shock were randomized to additional norepinephrine or vasopressin in doses up to 0.08 units/min. Four
hours after the additional vasopressors were
added, the norepinephrine dose was significantly lower than the baseline value in patients
randomized to vasopressin, with no statistically significantly change observed in the norepinephrine-only group. Similar dose-reducing
effects have been observed when vasopressin
is added to dopamine infusions [22]. Interestingly, the opposite effect was seen in our study
in that patients who received vasopressin plus
norepinephrine had statistically higher mean
cardiovascular SOFA scores and thus a higher
norepinephrine dose requirement over the first
seven days of vasopressor therapy. Another
potential benefit of the addition of vasopressin
to norepinephrine is the increases in glomerular filtration and urine output as a result of selective constriction of the glomerular efferent
arteriole when the drug is administered to patients with acute renal failure and septic shock
[30]. This effect has been observed clinically in
a number of trials; however, there are no data
to support this result beyond the first 24 h of
vasopressin infusion [18,19,21,29,31]. Again,
we found no difference in renal function, as
measured by SOFA scores, over the course of
14 days in patients who received vasopressin
and those who did not.
This is the second study that has associated
vasopressin with negative clinical outcomes.
We previously found vasopressin to be an independent predictor of in-hospital death in a
cohort of patients who received drotrecogin
alfa (activated) [23]. The explanation for this
finding may be related to end-organ ischemia
induced by vasopressin, manifested most obviously by ischemic skin lesions [32–34]. Lowdose vasopressin administration also has been
associated with increased splanchnic hypoperfusion [35–37] and a lower cardiac index when
added to norepinephrine [19,29]. These reports
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suggest taking a more cautionary stance to the
use of vasopressin in septic shock until the results of large randomized clinical trials examining its value become available.
Our investigation has several important limitations. First, it was performed in a single hospital, and the results may not be generalizable
to other treatment settings. Second, there were
no defined criteria for the addition of vasopressin to norepinephrine, partly because of
the lack of conclusive studies indicating which
patients may benefit. Third, we did not measure pre-treatment vasopressin concentrations
or determine which patients had vasopressin
deficiency. Most patients received vasopressin
within 48 h of presenting with septic shock and
beginning the norepinephrine infusion (Fig. 2),
suggesting that most of the vasopressin infusions were begun prior to overt vasopressin deficiency [13]. Fourth, patients receiving norepinephrine plus vasopressin appeared to have a
greater severity of illness, more organ derangements, and a greater likelihood of receiving drotrecogin alfa (activated). Although we
cannot discount the possibility that these baseline differences accounted for the greater mortality rate in this group, we applied two methods to control for potential variance. In both
the logistic regression and bipartite graphmatched analyses, patients who received vasopressin in combination with norepinephrine
had a statistically higher mortality rate than
those who did not. Therefore, the administration of vasopressin was associated with a
higher mortality rate independent of baseline
comorbidities included in the statistical models. Finally, we did not evaluate the role of
other potential therapies, hemodynamic status,
or sequential organ dysfunction that could interact specifically with vasopressin to influence
clinical outcomes. One example of this is the
adequacy of initial volume resuscitation. However, our subgroup analysis evaluating only
the patients receiving vasopressin found no differences in initial resuscitation volumes between survivors and nonsurvivors, making this
an unlikely explanation for the excess mortality associated with vasopressin administration.
In summary, our study found an association
between the use of vasopressin for refractory
septic shock and 28-day mortality. Prospective
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studies are needed to determine the role of vasopressin as a treatment for septic shock. In
view of its mechanism of action, there is the
possibility that vasopressin contributed directly to this excess mortality. Therefore, clinicians should be cautious about using vasopressin in patients with volume-refractory and
norepinephrine-dependent septic shock. Further recommendations regarding the use of vasopressin await the results of large randomized
trials.
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